ASO Visual Abstract: the role of adjuvant use of the PlasmaJet (R) device during cytoreductive surgery for advanced-stage ovarian cancer-results of the PlaComOv-Study, a randomized, controlled trial in the Netherlands

Nieuwenhuyzen-de Boer, G.M.; Hofhuis, W.; Reesink-Peters, N.; Willemsen, S.; Boere, I.A.; Schoots, I.G.; ... ; Beekhuizen, H.J. van

Ann Surg Oncol (2022) 29:4846–4847
https://doi.org/10.1245/s10434-022-11820-w

Annals of
SURGICAL ONCOLOGY
OFFICIAL JOURNAL OF THE SOCIETY OF SURGICAL ONCOLOGY

ASO VISUAL ABSTRACT

ASO Visual Abstract: The Role of Adjuvant Use of the PlasmaJet® Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer—Results of the PlaComOv-Study, a Randomized, Controlled Trial in the Netherlands

G. M. Nieuwenhuyzen-de Boer, MD[1,9], W. Hofhuis, MD, PhD[2], N. Reesink-Peters, MD, PhD[3], S. Willemsen, PhD[4,5], I. A. Boere, MD, PhD[6], I. G. Schoots, MD, PhD[7], J. M. J. Piek, MD, PhD[8], L. N. Hofman, MD[9], J. J. Beltman, MD, PhD[10], W. J. van Driel, MD, PhD[11], H. M. J. Werner, MD, PhD[12], A. Baalbergen, MD, PhD[13], A. M. L. D. van Haaften-de Jong, MD[14], M. Dorman, MD[15], L. Haans, MD[16], I. Nedelcu, MD[17], P. C. Ewing-Graham, MD[18], and H. J. van Beekhuizen, MD, PhD[1]

[1]Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; [2]Department of Obstetrics and Gynecology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands; [3]Department of Obstetrics and Gynecology, Medisch Spectrum Twente, Enschede, The Netherlands; [4]Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands; [5]Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands; [6]Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; [7]Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; [8]Department of Obstetrics and Gynecology, Catharina Cancer Institute, Eindhoven, The Netherlands; [9]Department of Obstetrics and Gynecology, Albert Schweitzer Hospital, Dordrecht, The Netherlands; [10]Department of Obstetrics and Gynecology, Leiden University Medical Centre, Leiden, The Netherlands; [11]Department of Gynecology, Center of Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands; [12]Department of Obstetrics and Gynecology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; [13]Department of Obstetrics and Gynecology, Reinier de Graaf Gasthuis, Delft, The Netherlands; [14]Department of Obstetrics and Gynecology, Haga Hospital, The Hague, The Netherlands; [15]Department of Obstetrics and Gynecology, Bravis Hospital, Bergen op Zoom, The Netherlands; [16]Department of Obstetrics and Gynecology, Haags Medical Centre, The Hague, The Netherlands; [17]Department of Obstetrics and Gynecology, Groene Hart Hospital, Gouda, The Netherlands; [18]Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

A total of 327 patients with FIGO stage IIIB-IV epithelial ovarian cancer (EOC) who underwent primary or interval cytoreductive surgery (CRS) were randomized to surgery with neutral argon plasma (PlasmaJet®) (intervention) or without PlasmaJet (control group) (https://doi.org/10.1245/s10434-022-11763-2).

Primary outcome was the percentage of complete CRS. Secondary outcomes were duration of surgery, blood loss, number of bowel resections and colostomies, hospitalization, 30 day-morbidity, and quality of life. The adjuvant use of the PlasmaJet during CRS for advanced-stage ovarian cancer resulted in a significant higher proportion of complete CRS in patients with resectable disease and a higher quality of life 6 months after surgery. (Funded by ZonMw, Trial Register NL62035.078.17.).

Published Online: 14 June 2022

G. M. Nieuwenhuyzen-de Boer, MD
e-mail: g.nieuwenhuyzen-deboer@erasmusmc.nl



DISCLOSURE Ingrid A. Boere—translational research (ctDNA) to the employer (Erasmus MC Cancer Institute) grant by GSK. Nieuwenhuyzen-de Boer—Grant from ZonMw received for the project. No relevant conflicts of interest.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.